Expert Review of Pharmacoeconomics & Outcomes Research

Article	Citations
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	30
Indication-based pricing of the pharmaceuticals in Croatia: case-study	23
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	21
How to create value with constrained budgets in oncological care? A narrative review	18
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	17
Social care data in the UK; current landscape, challenges, and future recommendations	16
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	16
Adherence to augmentation therapy for the treatment of major depressive disorder	16
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	15
A methodological guide for implementing and interpreting results of probabilistic analysis	13
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	13
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	13
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	13
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	12
Burden of disease and costs of infections associated with cardiac implantable electronic devices	12
Consumption of antidepressants and economic austerity in Brazil	11
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	11
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	11
The impact of under-investment on health in Southern and Central Eastern European Countries	11
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review	10
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	9
The role of insurance policies in the drug pricing landscape	9
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	9
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	9
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	9

The impact of bone turnover marker on medication adherence and the health economics-related consequences	9
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	8
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	8
Digital measures in epilepsy in low-resourced environments	8
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	8
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis	8
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	7
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	7
An update on the economic burden of type 2 diabetes mellitus in China	7
Systematic reviews of machine learning in healthcare: a literature review	7
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	7
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	7
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma	6
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	6
Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study	6
Estimation of the economic burden of atrial fibrillation-related stroke in Greece	6
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	6
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	6
How relevant is the BMI for cost-of-illness studies in the 21st century?	6
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	6
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	6
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	6
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	6
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	6
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	5
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	5
Valuing prevention: lessons and recommendations from a Dutch expert committee	5
Burden of disease of chronic pain in Ecuador	5
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	5
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	5
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	5
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	5
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	5
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data	5
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy	5
Bridging the gap: enhancing medication adherence through research and innovation	5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	5
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies	5
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	5
Developing the Lebanese health economic evaluation guideline	5
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	5
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	5
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	5
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	4
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	4
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	4
The economic impact of pharmacist intervention during pandemics	4

Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand	4
Economic benefits of global Collaborative Health technology	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
The hidden burden of atopic dermatitis in central and Eastern European countries	4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	4
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain	4
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	4
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	4
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer	4
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	4
Imputing missing patient-level data and propensity score matching in cost-effectiveness analysis in Crohn's disease	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	4
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
The Lebanese health economic evaluation guideline	4
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	4
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)	4
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	4
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	4
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	4
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	4
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	3
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	3
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	3
Correction	3
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
Cost and health impact analysis of herpes zoster vaccination in Norway	3
Barriers to digital endpoints in data collection in low and middle-income countries	3
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis	3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	3
Perspectives in prospective comparative economic evaluations: a systematic review	3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	3
The short-term impact of copayment reductions for government subsidised medicines in Australia	3
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece	3
Implementing a Managed Entry Agreement Framework in Cyprus	3
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	3
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece	3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population	3
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective	3
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves	3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	3
Burden of disease of chronic pain in Colombia	3
What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system	3
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024	3
Public value judgments about the criteria for reimbursement of medicines in South Korea	3
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	3
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	3
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	3
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	3
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds	3
Budget impact of low-dose computed tomography screening for lung cancer in Argentina	3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021	3
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China	3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model	3
Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia	3
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis	2
An exploratory cost-effectiveness analysis of a novel tissue valve compared with mechanical valves for surgical aortic valve replacement in subgroups of people aged 55–64 and 65+ with aortic stenosis	2
How should we measure the use of social care and informal care?	2
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia	2
Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc)	2
A review of caregiver costs included in cost-of-illness studies	2
Direct healthcare costs for people with cerebral palsy in the Brazilian unified health system between 2015 and 2019	2
What to expect in 2024: important health economics and outcomes research (HEOR) trends	2
The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review	2
The cost-of-illness of multiple sclerosis in Jordan	2
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	2
Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review including 321,850 pregnancies	2
Emerging trends: the involvement of community pharmacists in the planning and execution of pharmaceutical policies and economics	2
The impact of non-pharmacological interventions on adherence to medication and persistence in dyslipidaemia and hypertension: a systematic review	2
Pharmacovigilance and outcomes: experience from Saudi Arabia narrative review	2
Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study	2
Estimating cost-effectiveness of screening for colorectal cancer in Vietnam	2
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol	2
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	2

Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor	2
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	2
Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step	2
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis	2
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Sing	2
A landscape analysis and discussion of value of gene therapies for sickle cell disease	2
Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs	2
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	2
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health	2
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention	2
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	2
Integrated care in Western Europe: a wise solution for the future?	2
Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program	2
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	2
Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina	2
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	2
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare	2
Exploring the approach to parameter uncertainty in early economic evaluations of surgical technology – a systematic review	2
How unprofessional behaviours between healthcare staff threaten patient care and safety	2
Identification of cognitively impaired patients at risk for development of Alzheimer’s disease dementia: an analysis of US Medicare claims data	2
Payer and Developer perspectives on alternative payment models	2
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	2
Diabetes disparities in diabetes health care access and outcomes during the COVID-19 pandemic in the United States	2
Willingness to pay for a quality-adjusted life year (QALY) in Pakistan: implications for health policy	2
Correction	2
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	2
Economic evaluation of clinical pharmacy service using integrated health system in tertiary care hospital	2
The utility and impact of digital endpoints for improving breast cancer outcomes	2
Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	2
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	2
Is the shift in treatment patterns towards new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990–2022	2
How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions	2
Economic burden of suicides and suicide attempts in low- and middle-income countries: a systematic review of costing studies	2
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	2
Financial evaluation of value-creating biosimilar development candidates: a business case study of low-, medium- and high-sales biosimilars	2
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	2
A pre-vaccine analysis using the Health Belief Model to explain parents’ willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs	2
Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014	2
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore	1
Tackling reimbursement challenges to fair access to medicines – introduction to the topic	1
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension	1
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies	1
Cost of illness in multiple sclerosis by disease characteristics – A review of reviews	1
Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach	1
Cost-effectiveness of nintedanib versus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review	1
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer	1
Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma	1
HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework	1
Adapting Health Technology Assessment agency standards for surrogate outcomes in early stage cancer trials: what needs to happen?	1
Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study	1
First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis	1
Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia	1
Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions	1
Nonadherence to antiseizure medications: what have we learned and what can be done next?	1
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States	1
Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review	1
Economic and humanistic burden in kidney transplant rejection: a literature review	1
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?	1
Assessing smoking cessation services and pharmacotherapy in Namibia: findings and implications for future policy initiatives	1
Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada	1
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer	1
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China	1
Patient preferences in chronic immune-mediated inflammatory diseases potentially treated with biological drugs: discrete choice analysis using real-world data analysis	1
Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study	1
Letter to the editor regarding “Budget impact analysis of pneumococcal conjugate vaccines in Colombia”	1
Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis	1
Challenges in resource allocation of diagnostic tests in Spain	1
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspe	1
A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials	1
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?	1
Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit	1
Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China	1
A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries	1
Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database	1
A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany	1
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study	1
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?	1
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews	1
Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update	1
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework	1
Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy	1
All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain	1
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023	1
Cost-benefit analysis of hepatic resection, radiofrequency ablation and liver transplantation in small hepatocellular carcinoma	1
A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom	1
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment	1
Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder	1
Accounting for inflation within NICE cost-effectiveness thresholds	1
Content and cost of waste pharmaceuticals collected by pharmacies for disposal	1
Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis	1
Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia	1
Oxygen saturation thresholds for bronchiolitis at high altitudes: a cost-effectiveness analysis	1
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	1
Natural language processing – relevance to patient outcomes and real-world evidence	1
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma	1